Nasal potential difference in cystic fibrosis patients presenting borderline sweat test

The diagnosis of cystic fibrosis (CF) can be difficult if the sweat test and routine deoxyribonucleic acid (DNA) analysis are inconclusive. Under these circumstances, measurement of nasal potential difference (NPD) was proposed as a complementary diagnostic tool, as demonstrated in subjects bearing the G551S or 3849+10KbC-->T mutations. The purpose of the present study was to verify the diagnostic value of this technique in CF patients with a borderline sweat test. NPD was measured in 18 patients with a borderline sweat test, in whom CF diagnosis was based on the presence of one CF gene mutation in each chromosome (CF borderline). These patients were compared both to non-CF controls and CF patients with an abnormal sweat test (CF controls). Basal NPD values of CF borderline patients (mean value -39+/-6 mV, range -29 to -52 mV; n=18) were in the pathological range of CF controls (-39+/-8 mV, range -28 to -57 mV; n=37), and both were statistically different from values obtained in non-CF controls (-15+/-4 mV, range -6 to -23 mV; n=24; p<0.0001). Mutation analysis confirmed a high frequency of the 3849+10KbC-->T mutation in this group of CF borderline patients (positive in 14 out of 18 subjects), whereas other mutations, such as AF508, Q552X, N1303K and R1162X, were also found to be associated with this atypical CF phenotype. These results confirm the presence of pathological values of basal NPD in CF patients with borderline sweat test, and also extend this finding to subjects bearing genotypes other than the G551S and 3849+10KbC-->T mutations. The present findings, therefore, confirm the usefulness of measurement of basal nasal potential difference in all those patients in whom diagnosis of cystic fibrosis can be suspected but the sweat test remains inconclusive.

This article has been cited by other articles:

				A. K. M. Shamsuddin, M. M. Reddy, and P. M. Quinton Iontophoretic {beta}-adrenergic stimulation of human sweat glands: possible assay for cystic fibrosis transmembrane conductance regulator activity in vivo Exp Physiol, August 1, 2008; 93(8): 969 - 981. [Abstract] [Full Text] [PDF]

				K De Boeck, M Wilschanski, C Castellani, C Taylor, H Cuppens, J Dodge, M Sinaasappel, and on behalf of the Diagnostic Working Group Cystic fibrosis: terminology and diagnostic algorithms Thorax, July 1, 2006; 61(7): 627 - 635. [Abstract] [Full Text] [PDF]

				J. C. Davies, M. Davies, D. McShane, S. Smith, S. Chadwick, A. Jaffe, R. Farley, L. Collins, A. Bush, M. Scallon, et al. Potential Difference Measurements in the Lower Airway of Children with and without Cystic Fibrosis Am. J. Respir. Crit. Care Med., May 1, 2005; 171(9): 1015 - 1019. [Abstract] [Full Text] [PDF]

				M. Wilschanski, H. Famini, N. Strauss-Liviatan, J. Rivlin, H. Blau, H. Bibi, L. Bentur, Y. Yahav, H. Springer, M.R. Kramer, et al. Nasal potential difference measurements in patients with atypical cystic fibrosis Eur. Respir. J., June 1, 2001; 17(6): 1208 - 1215. [Abstract] [Full Text] [PDF]

				U. PRADAL, C. CASTELLANI, A. DELMARCO, and G. MASTELLA Nasal Potential Difference in Congenital Bilateral Absence of the Vas Deferens Am. J. Respir. Crit. Care Med., September 1, 1998; 158(3): 896 - 901. [Abstract] [Full Text] [PDF]